The effects of incretins as a double-edged sword on cancer
Molecular Biology Reports · 2025
DOI: 10.1007/s11033-025-11062-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Helia Mavaddat und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: Incretins, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Incretins, such as Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic peptide (GIP), are hormones known to stimulate insulin secretion and are widely used in the management of type 2 diabetes mellitus (T2DM). Recent evidence suggests that these hormones, and incretin-based therapies like DPP-4 inhibitors and GLP-1 receptor agonists, may have proliferative effects on pancreatic β-cells, raising concerns about a potential link to certain cancers. This review aims to evaluate both the beneficial and detrimental effects of incretins in cancer development and therapy. METHODS: We conducted a comprehensive review of clinical cohort studies, as well as in vivo and in vitro investigations, to assess the dual role of incretin-based therapies in cancer risk and potential treatment. The molecular and cellular mechanisms underlying these effects were critically analyzed. RESULTS: While some studies have suggested an increased risk of pancreatic, thyroid, cholangiocarcinoma, and colorectal cancers associated with incretin therapies-especially in genetically predisposed individuals-other research has demonstrated anticancer effects in prostate, breast, ovarian, and other cancers through various mechanisms. These include inhibition of tumor proliferation, induction of apoptosis, and modulation of immune responses. CONCLUSION: Although incretin-based drugs may pose a cancer risk in specific tissues, particularly in susceptible individuals, their therapeutic potential in mitigating other cancer types appears promising. The overall evidence suggests that the benefits of incretins may outweigh the risks when patient-specific factors are carefully considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
- GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
Zitieren
APA
Mavaddat, H., Fouladi, A., Peyrovinasab, A., Khayatan, I., Jalalian Targhi, H., Fakhri, M., Andarzbakhsh, K., Büsselberg, D., Razavi, S. M., & Rezazadeh, A. (2025). The effects of incretins as a double-edged sword on cancer. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-11062-5
Vancouver
Mavaddat H, Fouladi A, Peyrovinasab A, Khayatan I, Jalalian Targhi H, Fakhri M, et al. The effects of incretins as a double-edged sword on cancer. Molecular Biology Reports. 2025. doi:10.1007/s11033-025-11062-5
BibTeX
@article{Mavaddat2025,
author = {Mavaddat, Helia and Fouladi, Abtin and Peyrovinasab, Amirreza and Khayatan, Illia and Jalalian Targhi, Hanieh and Fakhri, Mojdeh and Andarzbakhsh, Kamyab and Büsselberg, Dietrich and Razavi, Seyed Mehrad and Rezazadeh, Amir},
title = {The effects of incretins as a double-edged sword on cancer},
journal = {Molecular Biology Reports},
year = {2025},
doi = {10.1007/s11033-025-11062-5}
}
EUVIMED